Muscle tears: classification and return to sport

The classification changes management from day one: a functional injury can settle within days on a progressive plan, whereas a 3B or type 4 tear needs weeks of structured rehabilitation and careful planning of the return to sport. Labelling the injury properly determines the imaging required, the prognosis and a realistic timeframe for competing again.

The clinical message: the main risk factor for the next injury is the last one, particularly when rehabilitation was left unfinished. And one finding worth holding on to before over-reading a scan: the authors conclude that recurrence risk is judged better from clinical data than from the MRI of the index injury.

The limitation the authors acknowledge is adherence. Later studies in professional leagues report low compliance, which dilutes the effect in the real world. It works if it is done, not if it is merely prescribed. Rehabilitation after a muscle injury still runs in phases (pain control → strength → functional loading → sport-specific movement → competition), and the return to sport is decided on functional criteria, not by the calendar and not by how the scan looks.

This is the finding that makes the classification useful to an athlete, because it puts numbers on the question everyone asks on day one. They should be read as medians for a group rather than as a personal date: the interquartile range for 3B injuries is 24 days, so two injuries carrying the same label can end up weeks apart.

Within the functional injuries there were no differences between subtypes, all falling between four and eight days. Only 5% of them progressed to a structural injury within two months, which supports not over-resting a complaint without a tear.

Two limits the authors themselves acknowledge. The type 4 group contained only five injuries, so its 60 days is indicative at best. And the medical team that classified each injury was the same one that later cleared the player, with no independent assessor, which can reinforce the agreement between label and timeframe.

What sets this study apart is that it measured the variables at the moment of clearance and then waited to see who broke down, rather than describing which criteria are used out of habit. That makes it one of the few references connecting a specific examination to what happens next.

No variable from the baseline MRI was associated with re-injury, a result worth remembering before resting a clearance decision on imaging.

It needs weighing carefully: with 17 re-injuries and four variables in the model, the confidence intervals are wide and overfitting is a real possibility. The strength and range-of-motion deficits were also associated with small increases per unit of deficit, so they only carry clinical weight when the difference between legs is appreciable, not for a minimal asymmetry.

The uncomfortable message from this literature is that no validated battery guarantees a safe return. Earlier reviews had already pointed out that the usual criteria, no pain, comparable strength and flexibility, and medical clearance, are applied almost universally without ever having been tested against re-injury.

That the athlete's own readiness appears among the better-supported criteria is not a footnote. Going back while feeling unsure is clinical information, not weakness, and it belongs in the decision alongside strength and mobility.

The review maps what is used and how well it is supported methodologically; it does not show that applying those criteria reduces re-injury. It includes male footballers only, so transferring it to other populations is a reasonable but untested extrapolation.

It is worth reading the other half of the result too: even with examination and MRI combined, two thirds of the variance remains unexplained. Giving an exact date on day one is imprudent with any test in hand.

Other work points the same way. MRI classification systems explain between 8% and 12% of the timeframe, and the size of the oedema between 6% and 12%. In a series of 53 athletes, 89% still showed abnormalities on imaging on the day they were cleared, and they competed anyway: waiting for the MRI to normalise is not a requirement.

Imaging does have another role. In the largest cohort to date, with 330 injuries, involvement of the myotendinous junction on the initial MRI was associated with a threefold risk of re-injury within a year. In other words, imaging says more about the risk of breaking down again than about the date of return, and those are two different questions.

As for ultrasound, the available evidence places it on a par with MRI in the acute phase, with 85% sensitivity and 84% specificity using MRI as the reference, plus the advantage of a dynamic examination in the same consultation. Its weak point is injuries involving the tendon, where agreement between the two tests falls to 60%, and long-term follow-up.